US Pharma MarketingAnalysts cut enGene cancer sales forecast after updated data widen gap to J&J
Leerink Partners analysts slashed their sales forecast for enGene Therapeutics’ bladder cancer candidate after phase 2 data dented their belief that the biotech can match rivals including Leerink Partners analysts slashed their sales forecast for enGene Therapeutics’ bladder cancer candidate after phase 2 data dented their belief that the biotech can match rivals including Johnson & Johnson. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation…
Leerink Partners analysts slashed their sales forecast for enGene Therapeutics’ bladder cancer candidate after phase 2 data dented their belief that the biotech can match rivals including Johnson & Johnson.
Source: FierceBiotech